Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?

Thorax

Volumn 69, Issue 1, 2014, Pages 72-79

  Vanfleteren, Lowie E G W ^a,b   Kocks, Janwillem W H ^c   Stone, Ian S ^d   Breyer Kohansal, Robab ^e   Greulich, Timm ^f   Lacedonia, Donato ^g   Buhl, Roland ^h   Fabbri, Leonardo M ⁱ   Pavord, Ian D ^j   Barnes, Neil ^d   Wouters, Emiel F M ^a,b   Agusti, Alvar ^k  

^a CIRO+   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d LONDON CHEST HOSPITAL   (United Kingdom)

^e OTTO WAGNER HOSPITAL   (Austria)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

^g UNIVERSITY OF FOGGIA   (Italy)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j GLENFIELD HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; STEROID;

ASTHMA; BIOINFORMATICS; CELL INTERACTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENVIRONMENTAL EXPOSURE; GENETICS; GENOMICS; HEALTH CARE DELIVERY; HISTORY OF MEDICINE; HUMAN; MEDICAL HISTORY; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL TERMINOLOGY; MEDICINE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; OSLERIAN PARADIGM; PARTICIPATORY MEDICINE; PATHOLOGY; PATIENT CARE; PATIENT PARTICIPATION; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SMOKING; TREATMENT RESPONSE;

ASTHMA; COPD MECHANISMS;

ASTHMA; DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYSTEMS BIOLOGY; TERMINOLOGY AS TOPIC;

EID: 84890316396     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203602     Document Type: Review

References (48)

1. Loscalzo J, Barabasi AL. Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med 2011;3:619-27.
2. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-51.
3. Loscalzo J, Kohane I, Barabasi AL. Human disease classi fication in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 2007;3:124.
4. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
5. Global strategy for asthma management and prevention. Updated 2011. http://www.ginasthma.org/. (accessed 17 Jun 2013).
6. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012;67:701-8.
7. O'Byrne PM, Pedersen S, Lamm CJ, et al. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19-24.
8. James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005;171:109-14.
9. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718.
10. Ballarin A, Bazzan E, Zenteno RH, et al. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:233-9.
11. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
12. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9.
13. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71.
14. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-8.
15. Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 2009;39:1652-8.
16. Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011;183:1129-37.
17. Freimer N, Sabatti C. The human phenome project. Nat Genet 2003;34:15-21.
18. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
19. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-25.
20. Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin de ficiency. Am J Respir Crit Care Med 2012;185:246-59.
21. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73.
22. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
23. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98.
24. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703.
25. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
26. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
27. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24.
28. Wardlaw AJ, Silverman M, Siva R, et al. Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005;35:1254-62.
29. Moore WC, Meyers DA, Wenzel SE, et al . Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010;181:315-23.
30. Lessard A, Turcotte H, Cormier Y, et al. Obesity and asthma: a specific phenotype? Chest 2008;134:317-23.
31. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322-9.
32. Cowan DC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010;65:384-90.
33. Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy 2010;40:62-7.
34. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008;372:1107-19.
35. Agusti A, Vestbo J. Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;184:507-13.
36. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.
37. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98.
38. Fens N, Roldaan AC, Van der Schee MP, et al. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy 2011;41:1371-8.
39. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009;34:812-18.
40. Garcia-Aymerich J, Gomez FP, Benet M, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax 2011;66:430-7.
41. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-35.
42. Celli BR, Cote CG, Marin JM, et al. The body-mass index, air flow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
43. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374:704-11.
44. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009;180:1189-95.
45. Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index - an outcome measure for use in children and adolescents. J Allergy Clin Immunol 2012;129:694-701.
46. Kupczyk M, Wenzel S. U.S. and European severe asthma cohorts: what can they teach us about severe asthma? J Intern Med 2012;272:121-32.
47. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010;137:1410-16.
48. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113-20.